Stockscreener 앱 받기
4.01
0.75%
0.03
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
What is HC Wainwright’s Forecast for LRMR FY2025 Earnings? - Defense World
William Blair Has Negative Estimate for LRMR Q1 Earnings - Defense World
FY2025 Earnings Estimate for LRMR Issued By HC Wainwright - MarketBeat
William Blair Has Pessimistic Outlook of LRMR Q1 Earnings - MarketBeat
Charles Schwab Investment Management Inc. Lowers Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Larimar Therapeutics announces initial data from OLE study of nomlabofusp - Yahoo Finance
Larimar Therapeutics (NASDAQ:LRMR) Given “Buy” Rating at HC Wainwright - Defense World
Why Is Larimar Therapeutics Stock Trading Lower On Monday? - AOL
Larimar Therapeutics' SWOT analysis: nomlabofusp's potential lifts stock outlook - Investing.com
Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
LRMR Stock Hits 52-Week Low at $3.79 Amid Market Fluctuations - Investing.com Australia
LRMR Stock Hits 52-Week Low at $3.79 Amid Market Fluctuations By Investing.com - Investing.com South Africa
Larimar Therapeutics stock plunges on clinical study concerns By Investing.com - Investing.com Canada
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Positive Initial Data from - GlobeNewswire
Larimar's Nomlabofusp Shows Breakthrough Results in Friedreich's Ataxia Treatment, FXN Levels Surge 72% - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Point72 Asset Management L.P. Sells 396,481 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
When (LRMR) Moves Investors should Listen - Stock Traders Daily
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN
Janus Henderson Group PLC Grows Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics's SWOT analysis: nomlabofusp progress lifts stock outlook By Investing.com - Investing.com Nigeria
Larimar Therapeutics's SWOT analysis: nomlabofusp progress lifts stock outlook - Investing.com India
Verition Fund Management LLC Decreases Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Fred Alger Management LLC Has $5.15 Million Stock Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Outperform Rating at William Blair - MarketBeat
Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times
Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire
Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from Analysts - MarketBeat
Nomlabofusp shows promise in Friedreich's ataxia study - Investing.com
(LRMR) Trading Signals - Stock Traders Daily
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com
Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com
Research Analysts Offer Predictions for LRMR FY2024 Earnings - Defense World
What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat
Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com
Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):